NCT05355805

Hidradenitis Suppurativa Phase 2b Study of Izokibep

A Phase 2b Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 205 (actual)
• Sponsor: ACELYRIN Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Izokibep is a potent and selective inhibitor of interleukin 17A (IL-17A) that is being developed for treatment of hidradenitis suppurativa (HS). This study will evaluate the efficacy, safety, and immunogenicity of izokibep administered subcutaneously (SC) in adult subjects with moderate to severe HS.

Conditions

• Hidradenitis Suppurativa

Interventions

Type	Name	Description
DRUG	Izokibep	Biologic: IL-17A inhibitor Form: Solution for injection Route of administration: Subcutaneous (SC)
DRUG	Placebo to izokibep	Form: Solution for injection Route of administration: Subcutaneous (SC)

Timeline

• Start date: 2022-05-05
• Primary completion: 2023-08-02
• Completion: 2024-02-21
• First posted: 2022-05-02
• Last updated: 2025-06-03
• Results posted: 2024-09-25

Locations

44 sites across 6 countries: United States, Canada, Germany, Hungary, Poland, Spain

Regulatory

• FDA-regulated drug study